Hospital Nossa Senhora da Conceição
Hospital Nossa Senhora da Conceição
Av. Francisco Trein, 596 – 2º andar - Bairro: Cristo Redentor - CEP 91350-200 - Porto Alegre
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Rodrigo Haas Bueno
Renata Marques
Andrea Kramer
Waldo Mattos
Carolina Heidtmann
Aline Santos
Andréa Kremer
Juliana de Menezes
Paula Paz
Leonardo Almeida
Gustavo Alves
Daltro Gilberto Boranga Junior
Franciele de Almeida Menegat
Mirela Gil
Liliana Rockenbach
Laisa Silveira
Mônica Terra Lima
Juliana Yamaguchi
Open studies
Lung cancer
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) - INTerpath-002 - Merck Sharp & Dohme LLCSee more
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) - MK-2870-019 - Merck Sharp & Dohme LLCSee more
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer - PolyDamas - Janssen Research & Development, LLCSee more
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] - MK-2870-023 - Merck Sharp & Dohme LLCSee more
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer - Krascendo 1 - Hoffmann-La RocheSee more
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) - INTerpath-009 - Merck Sharp & Dohme LLCSee more
Cardiovascular disease
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and CompanySee more
Head and neck cancer
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC - NANORAY-312 - NanobiotixSee more
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone - Boehringer IngelheimSee more
Pulmonary fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis - ALOFT-IPF - Bristol-Myers SquibbSee more
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis - ALOFT-PPF - Bristol-Myers SquibbSee more
Acute Coronary Syndrome
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome - LIBREXIA-ACS - Janssen Research & Development, LLCSee more
Breast Cancer
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) - heredERA - Hoffmann-La RocheSee more
Colorectal cancer
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer - MOUNTAINEER-03 - Seagen Inc.See more
Elevated Lipoprotein A
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) - ACCLAIM-Lp(a) - Eli Lilly and CompanySee more
Esophageal cancer
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) - MK-3475-06B - Merck Sharp & Dohme LLCSee more
Hypercholesterolemia
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes - CORALreef Outcomes - MK-0616-015 - Merck Sharp & Dohme LLCSee more
Solid tumors
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors - IMC-F106C-101 - Immunocore LtdSee more
Urothelial cancer
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 - KEYNOTE-D74 - Seagen Inc.See more
